Drug Trial Radar · NCT03886246
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
131
Actual
Start
May 29, 2019
Primary completion
Sep 30, 2027
Study completion Apr 27, 2028
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Boehringer Ingelheim
- First posted
- Mar 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to people with generalized pustular psoriasis (GPP). People can only take part if they have completed treatment in a previous study with spesolimab (1368-0013 or 1368-0027). The goal of this study is to find out how well people with GPP tolerate long-term treatment with spesolimab. The study also tests whether spesolimab helps improve GPP symptoms and how quickly the symptoms improve after a flare-up. Every participant gets spesolimab for almost 5 years (252 weeks). Depending on their symptoms and whether they had a GPP flare during the previous trial, they get spesolimab every few weeks. When participants have a GPP flare during this trial, they get spesolimab as an infusion into a vein. Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. To assess the study endpoints, doctors regularly check participants' skin.
Conditions
- Generalized Pustular Psoriasis
Interventions
SpesolimabDrug
Solution for infusion
SpesolimabDrug
Solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of treatment emergent adverse events (TEAEs) up to week 252 of maintenance treatmentTime frame: Up to 252 Weeks
Locations
58 sites in 21 countries. Site status is shown where the registry gives one.
Oakland Hills Dermatology
Auburn Hills, Michigan
Icahn School of Medicine at Mount Sinai
New York, New York
Hospital Italiano de Buenos Aires
CABA, Argentina
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Clínica Dermacross S.A.
Vitacura, Chile
Sun yet-sen Memorial Hospital, Sun yet-sen Univesity
Guangzhou, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
Shanghai Skin Disease Hospital
Shanghai, China
Huashan Hospital, Fudan University
Shanghai, China
Second Affiliated Hospital of Xi'an JiaoTong University
Xi'an, China
HOP Saint-André
Bordeaux, France
Hôpital de l'Archet
Nice, France
HOP Saint-Louis
Paris, France
HOP Robert Debré
Reims, France
Fachklinik Bad Bentheim
Bad Bentheim, Germany
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Bonn AöR
Bonn, Germany
Universitätsklinikum Erlangen
Erlangen, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany
Klinikum der Universität München - Campus Innenstadt
München, Germany
Westfälische Wilhelms-Universität Münster
Münster, Germany
Klinikum Oldenburg AöR
Oldenburg, Germany
Istituto Clinico Humanitas
Rozzano (MI), Italy
Nagoya City University Hospital
Aichi, Nagoya, Japan
Tokyo Medical University Ibaraki Medical Center
Ibaraki, Inashiki-gun, Japan
Saitama Medical University Hospital
Saitama, Iruma-gun, Japan
Tokyo Medical University Hachioji Medical Center
Tokyo, Hachioji, Japan
Hospital Pulau Pinang-Pulau Pinang-21953
George Town, Malaysia
Hospital Raja Permaisuri Bainun
Ipoh, Malaysia
Hospital Sultanah Aminah
Johor Bahru, Malaysia
Hospital Sultan Ismail
Johor Bahru, Malaysia
Queen Elizabeth Hospital
Kota Kinabalu, Malaysia
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia
Hospital Selayang
Kuala Selangor, Malaysia
Sarawak General Hospital
Kuching, Sarawak, Malaysia
Hospital Pakar Sultanah Fatimah
Muar town, Malaysia
Hospital Universitario Dr Jose Eleuterio Gonzalez
Monterrey, Mexico
Southern Philippines Medical Center -Davao-62091
Davao City, Philippines
Iloilo Doctors Hospital
Iloilo City, Iloilo, Philippines
Zenith Skin Science Center Inc.
Makati City, Philippines
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.